IS7227A - Salt form af E-2-metoxí-N-(3-(4-(3-metýl-pýridín-3-yloxýl)-fenýlamínó)-kínasólín-6-yl)-allýl)-asetamíð, framleiðsla þess og notkun gegn krabbameini - Google Patents

Salt form af E-2-metoxí-N-(3-(4-(3-metýl-pýridín-3-yloxýl)-fenýlamínó)-kínasólín-6-yl)-allýl)-asetamíð, framleiðsla þess og notkun gegn krabbameini

Info

Publication number: IS7227A
Authority: IS; Iceland
Prior art keywords: yloxyl; quinazolin; phenylamino; pyridin; acetamide
Prior art date: 2001-12-12

Application number

IS7227A

Other languages

English (en)

Inventor

Tyler Richter Daniel

Charles Kath John

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-12

Filing date

2004-04-19

Publication date

2004-04-19

2004-04-19 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2004-04-19 Publication of IS7227A publication Critical patent/IS7227A/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Oncology (AREA)
Reproductive Health (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

IS7227A 2001-12-12 2004-04-19 Salt form af E-2-metoxí-N-(3-(4-(3-metýl-pýridín-3-yloxýl)-fenýlamínó)-kínasólín-6-yl)-allýl)-asetamíð, framleiðsla þess og notkun gegn krabbameini IS7227A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34088501P	2001-12-12	2001-12-12
PCT/IB2002/004708 WO2003050108A1 (en)	2001-12-12	2002-11-11	Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer

Publications (1)

Publication Number	Publication Date
IS7227A true IS7227A (is)	2004-04-19

Family

ID=23335337

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7227A IS7227A (is)	2001-12-12	2004-04-19	Salt form af E-2-metoxí-N-(3-(4-(3-metýl-pýridín-3-yloxýl)-fenýlamínó)-kínasólín-6-yl)-allýl)-asetamíð, framleiðsla þess og notkun gegn krabbameini

Country Status (34)

Country	Link
US (1)	US6844349B2 (is)
EP (1)	EP1456199A1 (is)
JP (1)	JP4202926B2 (is)
KR (1)	KR20040065259A (is)
CN (1)	CN1608062A (is)
AP (1)	AP2004003059A0 (is)
AR (1)	AR037772A1 (is)
AU (1)	AU2002366581A1 (is)
BR (1)	BR0214876A (is)
CA (1)	CA2469889A1 (is)
DO (1)	DOP2002000544A (is)
EA (1)	EA007412B1 (is)
EC (1)	ECSP045148A (is)
GE (1)	GEP20063872B (is)
GT (1)	GT200200272A (is)
HR (1)	HRP20040530A2 (is)
HU (1)	HUP0402662A2 (is)
IL (1)	IL161915A0 (is)
IS (1)	IS7227A (is)
MA (1)	MA27095A1 (is)
MX (1)	MXPA04005678A (is)
NO (1)	NO20042925L (is)
NZ (1)	NZ532436A (is)
OA (1)	OA12735A (is)
PA (1)	PA8561401A1 (is)
PE (1)	PE20030716A1 (is)
PL (1)	PL370858A1 (is)
RS (1)	RS46404A (is)
TN (1)	TNSN04112A1 (is)
TW (1)	TW200301103A (is)
UA (1)	UA75482C2 (is)
UY (1)	UY27572A1 (is)
WO (1)	WO2003050108A1 (is)
ZA (1)	ZA200402995B (is)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL373848A1 (en) *	2001-12-12	2005-09-19	Pfizer Products Inc.	Quinazoline derivatives for the treatment of abnormal cell growth
AU2003249212C1 (en)	2002-07-15	2011-10-27	Symphony Evolution, Inc.	Receptor-type kinase modulators and methods of use
EP1575592A1 (en) *	2002-12-18	2005-09-21	Pfizer Products Inc.	4-anilino quinazoline derivatives for the treatment of abnormal cell growth
CN1726208A (zh) *	2002-12-19	2006-01-25	辉瑞产品公司	E－2－甲氧基－n－( 3－{4－[3－甲基－4－( 6－甲基－吡啶－3－基氧基)－苯基氨基]－喹唑啉－6－基}－烯丙基)－乙酰胺的配合物、其制备方法和用途
SG182849A1 (en)	2003-04-25	2012-08-30	Gilead Sciences Inc	Antiviral phosphonate analogs
BRPI0413745A (pt) *	2003-08-18	2006-10-24	Pfizer Prod Inc	horário mde dosagem para agentes anticancerìgenos erbb2
SI2392564T1 (sl)	2003-09-26	2014-02-28	Exelixis, Inc.	c-Met modulatorji in postopki uporabe
US7473696B2 (en) *	2003-10-27	2009-01-06	Merck & Co., Inc.	CCR-2 antagonist salt
US20050192298A1 (en) *	2004-02-27	2005-09-01	Pfizer Inc	Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
WO2005121124A1 (en) *	2004-06-07	2005-12-22	Pfizer Products Inc.	Complexes of e-2-methoxy-n-(3-{4-[3-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and methods of preparing same
PL1778251T3 (pl)	2004-07-27	2011-09-30	Gilead Sciences Inc	Koniugaty fosfonianowo-nukleozydowe jako środki przeciw wirusowi HIV
US20080194596A1 (en) *	2005-06-03	2008-08-14	Frizer Inc.	Therapeutic Combination Including a Selective Erbb2 Inhibitor
CA2610491A1 (en) *	2005-06-03	2006-12-07	Pfizer Products Inc.	Bicyclic derivatives for the treatment of abnormal cell growth
NZ572368A (en) *	2006-05-16	2011-04-29	Gilead Sciences Inc	Method and compositions for treating hematological malignancies
JPWO2008072634A1 (ja)	2006-12-12	2010-04-02	武田薬品工業株式会社	縮合複素環化合物
CN101611029B (zh) *	2006-12-21	2014-09-10	辉瑞产品公司	2-((4-(1-甲基-4-(吡啶-4-基)-1h-吡唑-3-基)苯氧基)甲基)喹啉的琥珀酸盐
AU2008236995A1 (en) *	2007-04-10	2008-10-16	Myrexis, Inc.	Dosages and methods for the treatment of cancer
AR070874A1 (es)	2008-03-12	2010-05-12	Takeda Pharmaceutical	Compuesto heterociclico fusionado, una composicion farmaceutica que lo comprende y su uso en el tratamiento del cancer.
US20100093667A1 (en)	2008-07-08	2010-04-15	Gilead Sciences, Inc.	Salts of hiv inhibitor compounds
CN110818633A (zh)	2009-01-16	2020-02-21	埃克塞里艾克西斯公司	一种苹果酸盐及其晶型
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US9265739B2 (en)	2010-06-02	2016-02-23	The Trustees Of The University Of Pennsylvania	Methods and use of compounds that bind to HER2/neu receptor complex
US8993634B2 (en)	2010-06-02	2015-03-31	The Trustees Of The University Of Pennsylvania	Methods and use of compounds that bind to Her2/neu receptor complex
US10420665B2 (en)	2010-06-13	2019-09-24	W. L. Gore & Associates, Inc.	Intragastric device for treating obesity
US8628554B2 (en)	2010-06-13	2014-01-14	Virender K. Sharma	Intragastric device for treating obesity
US10010439B2 (en)	2010-06-13	2018-07-03	Synerz Medical, Inc.	Intragastric device for treating obesity
US9526648B2 (en)	2010-06-13	2016-12-27	Synerz Medical, Inc.	Intragastric device for treating obesity
US9468681B2 (en)	2013-03-01	2016-10-18	California Institute Of Technology	Targeted nanoparticles
EP3795609B1 (en)	2015-07-01	2024-04-03	California Institute of Technology	Cationic mucic acid polymer-based delivery systems
US10779980B2 (en)	2016-04-27	2020-09-22	Synerz Medical, Inc.	Intragastric device for treating obesity
PL3661937T3 (pl)	2017-08-01	2021-12-20	Gilead Sciences, Inc.	Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
US20190381188A1 (en)	2018-06-13	2019-12-19	California Institute Of Technology	Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6884418B1 (en)	1989-08-04	2005-04-26	Berlex Laboratories, Inc.	Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
GB9510757D0 (en) *	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
GB9603095D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
ID19609A (id) *	1996-07-13	1998-07-23	Glaxo Group Ltd	Senyawa-senyawa heterosiklik
GEP20063831B (en) *	2000-06-22	2006-05-25	Pfizer Prod Inc	Substituted bicyclic derivatives for treatment of abnormal cell growth

2002
- 2002-11-11 CA CA002469889A patent/CA2469889A1/en not_active Abandoned
- 2002-11-11 WO PCT/IB2002/004708 patent/WO2003050108A1/en active IP Right Grant
- 2002-11-11 MX MXPA04005678A patent/MXPA04005678A/es active IP Right Grant
- 2002-11-11 EA EA200400674A patent/EA007412B1/ru not_active IP Right Cessation
- 2002-11-11 IL IL16191502A patent/IL161915A0/xx unknown
- 2002-11-11 NZ NZ532436A patent/NZ532436A/en unknown
- 2002-11-11 BR BR0214876-5A patent/BR0214876A/pt not_active IP Right Cessation
- 2002-11-11 JP JP2003551132A patent/JP4202926B2/ja not_active Expired - Fee Related
- 2002-11-11 UA UA20040604566A patent/UA75482C2/uk unknown
- 2002-11-11 AP APAP/P/2004/003059A patent/AP2004003059A0/en unknown
- 2002-11-11 EP EP02804543A patent/EP1456199A1/en not_active Withdrawn
- 2002-11-11 AU AU2002366581A patent/AU2002366581A1/en not_active Abandoned
- 2002-11-11 KR KR10-2004-7009073A patent/KR20040065259A/ko not_active Application Discontinuation
- 2002-11-11 RS YU46404A patent/RS46404A/sr unknown
- 2002-11-11 HU HU0402662A patent/HUP0402662A2/hu unknown
- 2002-11-11 CN CNA028248554A patent/CN1608062A/zh active Pending
- 2002-11-11 GE GE5562A patent/GEP20063872B/en unknown
- 2002-11-11 OA OA1200400161A patent/OA12735A/en unknown
- 2002-11-11 PL PL02370858A patent/PL370858A1/xx not_active Application Discontinuation
- 2002-12-06 TW TW091135465A patent/TW200301103A/zh unknown
- 2002-12-09 UY UY27572A patent/UY27572A1/es not_active Application Discontinuation
- 2002-12-10 AR ARP020104779A patent/AR037772A1/es unknown
- 2002-12-10 DO DO2002000544A patent/DOP2002000544A/es unknown
- 2002-12-10 US US10/315,862 patent/US6844349B2/en not_active Expired - Fee Related
- 2002-12-10 PE PE2002001185A patent/PE20030716A1/es not_active Application Discontinuation
- 2002-12-12 GT GT200200272A patent/GT200200272A/es unknown
- 2002-12-12 PA PA20028561401A patent/PA8561401A1/es unknown
2004
- 2004-04-19 IS IS7227A patent/IS7227A/is unknown
- 2004-04-20 ZA ZA200402995A patent/ZA200402995B/en unknown
- 2004-06-08 MA MA27730A patent/MA27095A1/fr unknown
- 2004-06-09 HR HR20040530A patent/HRP20040530A2/hr not_active Application Discontinuation
- 2004-06-11 EC EC2004005148A patent/ECSP045148A/es unknown
- 2004-06-11 TN TNP2004000112A patent/TNSN04112A1/fr unknown
- 2004-07-09 NO NO20042925A patent/NO20042925L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP0402662A2 (hu)	2005-05-30
EA200400674A1 (ru)	2004-10-28
JP4202926B2 (ja)	2008-12-24
PL370858A1 (en)	2005-05-30
KR20040065259A (ko)	2004-07-21
BR0214876A (pt)	2004-12-28
NO20042925L (no)	2004-09-07
NZ532436A (en)	2006-01-27
CN1608062A (zh)	2005-04-20
AR037772A1 (es)	2004-12-01
GT200200272A (es)	2003-12-12
MA27095A1 (fr)	2004-12-20
EP1456199A1 (en)	2004-09-15
US6844349B2 (en)	2005-01-18
ZA200402995B (en)	2005-04-20
AP2004003059A0 (en)	2004-06-30
EA007412B1 (ru)	2006-10-27
TNSN04112A1 (fr)	2006-06-01
HRP20040530A2 (en)	2004-10-31
US20030158217A1 (en)	2003-08-21
PA8561401A1 (es)	2005-02-04
JP2005511744A (ja)	2005-04-28
TW200301103A (en)	2003-07-01
PE20030716A1 (es)	2003-08-29
UY27572A1 (es)	2003-07-31
WO2003050108A1 (en)	2003-06-19
WO2003050108A8 (en)	2003-12-18
UA75482C2 (en)	2006-04-17
AU2002366581A1 (en)	2003-06-23
CA2469889A1 (en)	2003-06-19
RS46404A (en)	2006-10-27
DOP2002000544A (es)	2003-06-16
MXPA04005678A (es)	2004-12-06
GEP20063872B (en)	2006-07-10
OA12735A (en)	2006-06-29
ECSP045148A (es)	2004-07-23
IL161915A0 (en)	2005-11-20

Publication	Publication Date	Title
IS7227A (is)	2004-04-19	Salt form af E-2-metoxí-N-(3-(4-(3-metýl-pýridín-3-yloxýl)-fenýlamínó)-kínasólín-6-yl)-allýl)-asetamíð, framleiðsla þess og notkun gegn krabbameini
DK1438306T3 (da)	2014-06-23	Derivater af UK-2A
DK1360169T3 (da)	2007-11-26	Succinatsalt af O-desmethyl-venlafaxin
DK1278350T3 (da)	2012-08-27	Autentificering af verificering for mobilbrugere
DK1417175T3 (da)	2013-10-28	Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
IS7007A (is)	2003-10-30	Kristallaform af asiþrómýsíni
DK1417180T3 (da)	2007-04-10	Fremstilling af aminopyrimidinforbindelser
DE50213336D1 (de)	2009-04-16	Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre verwendung
DE50207849D1 (de)	2006-09-28	Substituierte 2-oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung
DE50212455D1 (de)	2008-08-14	Verwendung von Dimerdiolen
DK1651644T3 (da)	2007-03-26	Substituerede derivater af thiazol-benzoisothiazoldioxid, fremgangsmåde deraf og deres anvendelse
NO20033679D0 (no)	2003-08-19	Nye pyrimidinforbindelser
DE60229183D1 (de)	2008-11-20	Leitschaufel-Verstellantrieb
DK1432417T3 (da)	2008-06-16	Substituerede imidazolforbindelser og deres anvendelse til behandling af cancer
DK1572169T3 (da)	2013-10-21	Påvisning og modulering af Slit- og Robo-medieret angiogenese og anvendelser deraf
DK1354027T3 (da)	2006-11-06	Stabilisering af drikkevarer
NO20035573L (no)	2004-02-16	Kinazolinderivater
NO20041968L (no)	2004-05-11	Anvendelse av cystationin
DE60126734D1 (de)	2007-04-05	Superiostealer Knochenanker
NO20042613L (no)	2004-08-13	Ny anvendelse for behandling av gastroosofagial refluks
ATE459085T1 (de)	2010-03-15	Temperaturbegrenzer
EE200200496A (et)	2004-02-16	4-amino-6,7-dimetoksü-2-(5-metaansulfoonamido-1,2,3,4-tetrahüdroisokinool-2-üül)-5 -(2-püridüül)kinasoliinmesülaat ja selle polümorfid
DK1786759T3 (da)	2012-10-15	Nye derivater af 3,5-seco-4-nor-cholestan og deres anvendelser
DK1427724T3 (da)	2006-08-21	Hidtil ukendt anvendelse af substituerede aminomethylchromaner
DK1472412T3 (da)	2008-03-31	Byggesæt af brosten